In children with type 1 diabetes, pramlintide reduced immediate postprandial hyperglycemia, whereas increased insulin did not.
In plain wordsIn children with type 1 diabetes, pramlintide reduced early glucose rises after meals, whereas increased insulin did not.
- Peptide
- Pramlintide (Symlin)
- Outcome
- DecreaseImmediate postprandial hyperglycemia
- Study
n = 8
- Comparator
- 60% increase in insulin bolus-to-carbohydrate ratio (with minidose glucagon rescue)
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 30-45 microgAs given in this study (human).
Measurements
- Glucose AUC (0-180 min)
- 470 mg x h(-1) x dl(-1)
- first value of reported pair; group order not stated
- Glucose AUC (0-180 min)
- 434 mg x h(-1) x dl(-1)
- second value of reported pair; group order not stated
Source sentences
Pramlintide, but not an increase in insulin, reduced immediate postprandial hyperglycemia (AUC(0-180 min) 470 +/- 43 vs. 434 +/- 48 mg x h(-1) x dl(-1), P < 0.01).
4 context sentences(design, population, supporting numbers)
A total of 11 control subjects were compared with 8 type 1 diabetic subjects on insulin pump therapy, using the usual insulin bolus-to-carbohydrate ratio during a standard liquid meal.
Type 1 diabetic subjects were then randomized to two open-labeled studies.
On one occasion, type 1 diabetic subjects received a 60% increase in the insulin bolus-to-carbohydrate ratio with minidose glucagon rescue injections, and on the other occasion type 1 diabetic subjects received 30-45 microg pramlintide with their usual insulin bolus-to-carbohydrate ratio.
Glucose, glucagon, amylin (pramlintide), and insulin concentrations were measured for 420 min.